PFE vs. CLS
PFE (Pfizer Inc.) and CLS (Celestica Inc.) are both stocks. PFE operates in Drug Manufacturers - General (Healthcare), while CLS operates in Electronic Components (Technology). Over the past 10 years, PFE returned 2.11%/yr vs 43.71%/yr for CLS. At a 0.20 correlation, their price movements are largely independent.
Performance
PFE vs. CLS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, PFE achieves a 8.79% return, which is significantly lower than CLS's 32.99% return. Over the past 10 years, PFE has underperformed CLS with an annualized return of 2.11%, while CLS has yielded a comparatively higher 43.71% annualized return.
PFE
- 1D
- 0.15%
- 1M
- 1.79%
- YTD
- 8.79%
- 6M
- 4.79%
- 1Y
- 14.27%
- 3Y*
- -7.78%
- 5Y*
- -3.35%
- 10Y*
- 2.11%
CLS
- 1D
- 1.88%
- 1M
- 3.02%
- YTD
- 32.99%
- 6M
- 28.26%
- 1Y
- 213.67%
- 3Y*
- 207.28%
- 5Y*
- 116.26%
- 10Y*
- 43.71%
PFE vs. CLS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
PFE Pfizer Inc. | 8.79% | 0.65% | -2.22% | -41.26% | -10.41% | 66.70% | 3.07% | -6.91% | 24.82% | 15.90% |
CLS Celestica Inc. | 32.99% | 220.27% | 215.23% | 159.80% | 1.26% | 37.92% | -2.42% | -5.70% | -16.32% | -11.56% |
Correlation
The correlation between PFE and CLS is -0.07, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.07 |
Correlation (3Y) Calculated over the trailing 3-year period | -0.02 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.08 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.13 |
Correlation (All Time) Calculated using the full available price history since Jun 30, 1998 | 0.20 |
The correlation between PFE and CLS shifts across timeframes, from -0.07 (1 year) to 0.20 (all time), reflecting how their relationship changes across market environments.
Fundamentals
PFE:
$150.21B
CLS:
$45.48B
PFE:
$1.31
CLS:
$8.28
PFE:
19.98
CLS:
47.45
PFE:
0.36
CLS:
0.64
PFE:
2.36
CLS:
3.30
PFE:
1.67
CLS:
21.68
PFE:
$63.32B
CLS:
$13.81B
PFE:
$43.91B
CLS:
$1.60B
PFE:
$16.94B
CLS:
$1.32B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
PFE vs. CLS — Risk / Return Rank
PFE
CLS
PFE vs. CLS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Pfizer Inc. (PFE) and Celestica Inc. (CLS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PFE | CLS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -2.24 | ||
| Sortino ratioReturn per unit of downside risk | -1.82 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.37 | -0.25 |
| Calmar ratioReturn relative to maximum drawdown | 1.13 | 6.91 | -5.78 |
| Martin ratioReturn relative to average drawdown | 2.27 | 16.83 | -14.56 |
Loading charts...
Drawdowns
PFE vs. CLS - Drawdown Comparison
The maximum PFE drawdown since its inception was -69.24%, smaller than the maximum CLS drawdown of -96.93%. Use the drawdown chart below to compare losses from any high point for PFE and CLS.
Loading charts...
Drawdown Indicators
| PFE | CLS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -69.24% | -96.93% | +27.69% |
Max Drawdown (1Y)Largest decline over 1 year | -11.47% | -29.24% | +17.77% |
Max Drawdown (3Y)Largest decline over 3 years | -40.43% | -53.96% | +13.53% |
Max Drawdown (5Y)Largest decline over 5 years | -58.96% | -53.96% | -5.00% |
Max Drawdown (10Y)Largest decline over 10 years | -58.96% | -80.60% | +21.64% |
Current DrawdownCurrent decline from peak | -45.68% | -16.78% | -28.90% |
Average DrawdownAverage peak-to-trough decline | -22.90% | -73.31% | +50.41% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.70% | 11.98% | -6.28% |
Volatility
PFE vs. CLS - Volatility Comparison
The current volatility for Pfizer Inc. (PFE) is 5.07%, while Celestica Inc. (CLS) has a volatility of 27.54%. This indicates that PFE experiences smaller price fluctuations and is considered to be less risky than CLS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| PFE | CLS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.07% | 27.54% | -22.47% |
Volatility (6M)Calculated over the trailing 6-month period | 14.62% | 55.42% | -40.80% |
Volatility (1Y)Calculated over the trailing 1-year period | 23.84% | 72.65% | -48.81% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 25.48% | 57.70% | -32.22% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.89% | 49.97% | -26.08% |
Dividends
PFE vs. CLS - Dividend Comparison
PFE's dividend yield for the trailing twelve months is around 6.56%, while CLS has not paid dividends to shareholders.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CLS Celestica Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
PFE Pfizer Inc. | 6.56% | 6.91% | 6.33% | 5.70% | 3.12% | 2.64% | 3.92% | 3.68% | 3.12% | 3.53% | 3.69% | 3.47% |
Financials
PFE vs. CLS - Financials Comparison
This section allows you to compare key financial metrics between Pfizer Inc. and Celestica Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
PFE vs. CLS - Profitability Comparison
PFE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a gross profit of 9.72B and revenue of 14.45B. Therefore, the gross margin over that period was 67.3%.
CLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.
PFE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported an operating income of 4.03B and revenue of 14.45B, resulting in an operating margin of 27.9%.
CLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 272.10M and revenue of 4.05B, resulting in an operating margin of 6.7%.
PFE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Pfizer Inc. reported a net income of 2.69B and revenue of 14.45B, resulting in a net margin of 18.6%.
CLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.
Frequently Asked Questions
PFE and CLS have a correlation of -0.07, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLS has higher volatility (27.54%) compared to PFE (5.07%). In terms of maximum drawdown, PFE dropped -69.24% vs CLS's -96.93%.
CLS currently has the higher Sharpe Ratio (2.78 vs 0.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for PFE and CLS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer